

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 262 - Saudi Arabia

28 October - 3 November, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	247,472,724	5,012,337	16,399,307	302,073
Last Week	244,385,444	4,961,489	16,283,923	299,804

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	548,760	537,690	8,799	2,246	54	30,389,463
in 7 days						
27/10/2021	51	35	3	2,233	59	44,822
28/10/2021	56	49	2	2,238	64	47,620
29/10/2021	41	32	3	2,244	66	45,594
30/10/2021	46	36	1	2,253	61	45,650
31/10/2021	49	35	2	2,239	61	34,149
1/11/2021	45	48	2	2,234	59	35,972
2/11/2021	49	37	1	2,246	54	39,750

Vaccination in KSA

Total Doses Administered	Total of 1 Dose	Total of 2 Doses	Total of 3 Doses
46.2 million	24.3 million	21.7 million	0.3 million

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Riyadh followed by Makkah.
- SFDA has approved to include children of 5-11 years to receive the Pfizer vaccine (BNT162b2) in the Kingdom.
- Minister of Health announced that 70% of population vaccinated against COVID-19 with 2 doses.
- Ministry of Interior: wearing masks and maintaining physical distancing are mandatory for entering stadiums and big event halls.
- Ministry of Education has decided to conduct exams for students of elementary schools remotely at the end of the first semester.
- Ministry of Interior has started issuing institutional quarantine premises licenses for unvaccinated workers from outside the Kingdom from the countries that are not facing travel ban.
- Ministry of Interior urged all citizens and expatriates to receive booster dose of coronavirus vaccine once they completed 6 months after taking the 2nd dose.
- Ministry of Interior records 742 violations against precautionary measures nationally in 1 week. The highest number was recorded in the Riyadh Region whereas the smallest number was in Northern Borders.
- WHO has developed a clinical case definition of post COVID-19 condition by Delphi methodology that includes 12 domains, see link.
- WHO publishes WHO COVID-19 Excess Mortality Estimation Methodology, see link.
- WHO's Scientific Brief on Neurology and COVID-19 highlights the relationship between neurology and COVID-19, see link.
- WHO publishes recommendations on the Co-administration of seasonal inactivated influenza and COVID-19 vaccines, see link.
- WHO publishes technical specifications and implementation guidance for digital documentation of COVID-19 vaccination status, see link.
- WHO publishes holding gatherings during the COVID-19 pandemic: WHO policy brief, see link.
- WHO publishes An overview of infodemic management during COVID-19, January 2020–May 2021, see link.

IMPORTANT LINKS

- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **A clinical case definition of post COVID-19 condition by a Delphi consensus:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
- **WHO COVID-19 Excess Mortality Estimation Methodology:** <https://www.who.int/publications/i/item/who-covid-19-excess-mortality-estimation-methodology>
- **Neurology and COVID-19: Scientific brief, 29 September:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Neurology-2021.1>
- **WHO recommendations on the co-administration of COVID-19 and influenza vaccines:** [Coadministration of seasonal inactivated influenza and COVID-19 vaccines \(who.int\)](https://www.who.int/publications/i/item/Coadministration-of-seasonal-inactivated-influenza-and-COVID-19-vaccines-(who.int))
- **Digital Documentation of COVID-19 Certificates: Vaccination Status:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Digital-certificates-vaccination-technical_briefing-2021.1
- **Holding gatherings during the COVID-19 pandemic: WHO policy brief:** <https://www.who.int/publications/i/item/holding-gatherings-during-the-covid-19-pandemic-who-policy-brief-2-august-2021>
- **An overview of infodemic management during COVID-19, January 2020–May 2021:** <https://www.who.int/publications/i/item/9789240035966>

IMPORTANT DEVELOPMENTS

WHO issues emergency use listing for COVAXIN® COVID-19 vaccine





The World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN® (developed by Bharat Biotech - India), on 3 November 2021 for the prevention of COVID-19.

COVAXIN® was assessed under the WHO EUL procedure based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability. The Technical Advisory Group (TAG), convened by WHO has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used globally.

The vaccine is formulated from an inactivated SARS-CoV-2 antigen. WHO recommends the use of the vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above. COVAXIN® was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements. Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned.

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.

Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products said “This emergency use listing expands the availability of vaccines, the most effective medical tool we have to end the pandemic,”



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa